Risk-based Monitoring Software Market by End User (Pharma & Biopharmaceutical Co., Medical Device Co., CROs), Delivery Mode (Web Hosted, On-premise, Cloud-based), Type (Enterprise, Site), Component (Software, Services) - Global Forecast to 2025

リスクベース監視ソフトウェアの世界市場予測:エンドユーザー別(製薬&バイオ製薬株式会社、医療機器株式会社、CRO)、配信モード別(Webホスト、オンプレミス、クラウドベース)、タイプ別(エンタープライズ、サイト)、コンポーネント別(ソフトウェア、サービス)

◆タイトル:Risk-based Monitoring Software Market by End User (Pharma & Biopharmaceutical Co., Medical Device Co., CROs), Delivery Mode (Web Hosted, On-premise, Cloud-based), Type (Enterprise, Site), Component (Software, Services) - Global Forecast to 2025
◆商品コード:HIT 7651
◆調査・発行会社:MarketsandMarkets
◆発行日:2020年5月29日
◆ページ数:138
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥529,650見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥711,550見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥872,050見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

MarketsandMarkets社はリスクベース監視ソフトウェアの世界市場が2020年2億7300万ドルから2025年5億1100万ドルまで、年平均13.3%%成長すると予測しています。本調査レポートでは、リスクベース監視ソフトウェアの世界市場を詳細に調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、種類別(エンタープライズRBMソフトウェア、ソフトウェアRBMサイト)、コンポネント別(ソフトウェア、サービス)、エンドユーザー別(製薬&生物医薬品会社、契約調査組織(CROS)、医療機器会社、その他エンドユーザー)、地域別、競争状況、企業概要などを含め、ご提供いたします。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・リスクベース監視ソフトウェアの世界市場:種類別(エンタープライズRBMソフトウェア、ソフトウェアRBMサイト)
・リスクベース監視ソフトウェアの世界市場:コンポネント別(ソフトウェア、サービス)
・リスクベース監視ソフトウェアの世界市場:配信モード別(ウェブベース(オンデマンド)、ライセンス企業(オンプレミス)、クラウドベース(SAAS))
・リスクベース監視ソフトウェアの世界市場:エンドユーザー別(製薬&生物医薬品会社、契約調査組織(CROS)、医療機器会社、その他エンドユーザー)
・リスクベース監視ソフトウェアの世界市場:地域別
・競争状況
・企業概要

“Risk-based monitoring (RBM) software market is projected to grow at a CAGR of 13.3%.”
The RBM software market is expected to reach USD 511 million by 2025 from USD 273 million in 2020, at a CAGR of 13.3% during the forecast period. The RBM software market has witnessed various advancements in products and their approvals to meet the needs of the pharmaceutical research and development industry worldwide.
Growth in the market can primarily be attributed to factors such as the cost and time efficiency of RBM solutions, rising number of clinical trials, and increasing government funding and grants to support clinical trials

“The Enterprise RBM Software segment to hold the largest market share in 2020.”
Based on type, the RBM software market is segmented into Enterprise RBM Software and Site RBM Software. In 2020, the Enterprise RBM Software segment is expected to command the largest share of the RBM software market. The large share of this segment can be attributed to the widespread adoption of enterprise RBM software by end-users as it allows all authorized professionals to have access to clinical trial data and metrics placed at a centralized location.

“The software component segment to hold the largest market share in 2020.”
Based on the component, the RBM software market is segmented into Software and Services. In 2020, the software segment is expected to command the largest share of the RBM software market. The large share of this segment can be attributed to the increasing R&D expenditure in the life science and clinical research industries, increasing number of clinical trials, and rising customer base

“The pharmaceutical and biopharmaceutical companies segment to hold the largest market share in 2020.”
Based on end-user, the RBM software market is segmented into pharmaceutical and biopharmaceutical companies, CROs, medical device companies, and other end users. In 2020, the pharmaceutical and biopharmaceutical companies segment is expected to command the largest share of the RBM software market. The increasing R&D expenditure of pharmaceutical and biopharmaceutical companies is the major factor driving the growth of this end-user segment.

“The Asia Pacific region to witness the highest growth during the forecast period.”
Geographically, North America dominated the global RBM software market in 2020. However, the Asia Pacific market is expected to register the highest during the forecast period. The major factors driving the growth of the Asia Pacific market include increasing government funding to support clinical trials, the presence of less stringent regulatory guidelines as compared to developed nations, a large patient base, low operating costs for conducting clinical trials, shortage of trial volunteers in Europe and North America, and the growing number of pharmaceutical companies and CROs in the region.

Break of primary participants was as mentioned below:
 By Company Type: Tier I: 55%, Tier II: 25%, Tier III: 20%
 By Designation: C-Level Executives: 35%, Directors: 25%, Others: 40%
 By Region: North America: 20%, Europe: 25%, Asia Pacific : 40%, RoW: 15%
Oracle (US), Medidata Solutions (US), and Parexel International Corporation (US) were the leading players in the RBM software market.
Research Coverage
This report studies the RBM software market based on type, component, delivery mode, end-user, and region. The report also studies the different factors (such as drivers, restraints, challenges, and opportunities) affecting the market growth. It analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to four main regions and respective countries.

Key Benefits of Buying the Report
This report focuses on various levels of analysis—industry trends, market shares of top players, and company profiles, which together form basic views and analyze the competitive landscape, emerging segments of the RBM software market, and their drivers, restraints, and opportunities. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the RBM software and garner greater market shares.

【レポートの目次】

TABLE OF CONTENTS

1 INTRODUCTION (Page No. – 17)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 MARKET SCOPE
1.2.2 MARKETS COVERED
1.2.3 YEARS CONSIDERED FOR THE STUDY
1.3 CURRENCY
1.4 LIMITATIONS
1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY (Page No. – 20)
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Primary sources
2.1.3 MARKET SIZE ESTIMATION METHODOLOGY
2.1.4 REVENUE MAPPING-BASED MARKET ESTIMATION (APPROACH 1)
2.1.5 MARKET ESTIMATION USING PARENT MARKET SIZE (APPROACH 2)
2.2 MARKET DATA ESTIMATION AND TRIANGULATION
2.3 ASSUMPTIONS OF THE STUDY

3 EXECUTIVE SUMMARY (Page No. – 30)

4 PREMIUM INSIGHTS (Page No. – 34)
4.1 RISK-BASED MONITORING SOFTWARE: MARKET OVERVIEW
4.2 RISK-BASED MONITORING SOFTWARE MARKET SHARE, BY TYPE, 2020 VS. 2025
4.3 RISK-BASED MONITORING SOFTWARE MARKET SHARE, BY COMPONENT, 2020 VS. 2025
4.4 RISK-BASED MONITORING SOFTWARE MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW (Page No. – 36)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Cost and time efficiency of RBM solutions
5.2.1.2 Rising number of clinical trials
5.2.1.3 Increasing government funding and grants to support clinical trials
5.2.2 RESTRAINTS
5.2.2.1 High implementation costs
5.2.3 OPPORTUNITIES
5.2.3.1 Increased outsourcing of clinical trial processes to CROs
5.2.4 CHALLENGES
5.2.4.1 Dearth of skilled professionals for operating RBM solutions

6 RISK-BASED MONITORING SOFTWARE MARKET, BY TYPE (Page No. – 40)
6.1 INTRODUCTION
6.2 ENTERPRISE RBM SOFTWARE
6.2.1 ENTERPRISE RBM SOFTWARE DOMINATES THE RBM SOFTWARE MARKET
6.3 SITE RBM SOFTWARE
6.3.1 SITE RBM SOFTWARE OFFERS IMPROVED TRIAL MANAGEMENT

7 RISK-BASED MONITORING SOFTWARE MARKET, BY COMPONENT (Page No. – 45)
7.1 INTRODUCTION
7.2 SOFTWARE
7.2.1 GROWING ADOPTION OF CLINICAL TRIAL MANAGEMENT SOLUTIONS TO SUPPORT MARKET GROWTH
7.3 SERVICES
7.3.1 NEED FOR CONTINUOUS UPGRADE OF RBM SOFTWARE PRODUCTS HAS INCREASED THE DEMAND FOR SERVICES

8 RISK-BASED MONITORING SOFTWARE MARKET, BY DELIVERY MODE (Page No. – 50)
8.1 INTRODUCTION
8.2 WEB-BASED (ON-DEMAND)
8.2.1 ADVANTAGES SUCH AS EASY ACCESS & REDUCTION IN COSTS TO SUPPORT MARKET GROWTH
8.3 LICENSED ENTERPRISE (ON-PREMISE)
8.3.1 ON-PREMISE MODELS MINIMIZE RISKS ASSOCIATED WITH DATA BREACHES AND EXTERNAL ATTACKS
8.4 CLOUD-BASED (SAAS)
8.4.1 INCREASING ADOPTION OF CLOUD-BASED SOLUTIONS TO DRIVE MARKET GROWTH

9 RISK-BASED MONITORING SOFTWARE MARKET, BY END USER (Page No. – 57)
9.1 INTRODUCTION
9.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
9.2.1 INCREASED PHARMACEUTICAL R&D SPENDING TO DRIVE MARKET GROWTH
9.3 CONTRACT RESEARCH ORGANIZATIONS (CROS)
9.3.1 INCREASING OUTSOURCING OF CLINICAL RESEARCH ACTIVITIES BY PHARMACEUTICAL, BIOTECHNOLOGY, AND MEDICAL DEVICE COMPANIES TO DRIVE MARKET GROWTH
9.4 MEDICAL DEVICE COMPANIES
9.4.1 GOVERNMENT FUNDING TO SUPPORT MARKET GROWTH
9.5 OTHER END USERS

10 RISK-BASED MONITORING SOFTWARE MARKET, BY REGION (Page No. – 66)
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 US
10.2.1.1 The US holds the largest share of the North American market
10.2.2 CANADA
10.2.2.1 Government funding to boost market growth
10.3 EUROPE
10.3.1 GERMANY
10.3.1.1 Initiatives to boost digital health to propel market growth
10.3.2 UK
10.3.2.1 Favorable R&D scenario in the country to boost the adoption of RBM software
10.3.3 FRANCE
10.3.3.1 Lack of sufficient funding to restrain market growth in France
10.3.4 ROE
10.4 APAC
10.4.1 CHINA
10.4.1.1 Increased pharmaceutical R&D spending to drive market growth
10.4.2 JAPAN
10.4.2.1 Stringent regulatory scenario in Japan to restrain market growth
10.4.3 INDIA
10.4.3.1 Favorable pharmaceutical R&D scenario to drive the adoption of RBM software
10.4.4 REST OF ASIA PACIFIC
10.5 REST OF THE WORLD

11 COMPETITIVE LANDSCAPE (Page No. – 96)
11.1 OVERVIEW
11.2 MARKET SHARE ANALYSIS
11.3 COMPETITIVE LEADERSHIP MAPPING
11.3.1 VISIONARY LEADERS
11.3.2 INNOVATORS
11.3.3 DYNAMIC DIFFERENTIATORS
11.3.4 EMERGING COMPANIES
11.4 COMPETITIVE SCENARIO
11.4.1 PRODUCT LAUNCHES & ENHANCEMENTS
11.4.2 FUNDING
11.4.3 ACQUISITIONS
11.4.4 PARTNERSHIPS
11.4.5 COLLABORATIONS

12 COMPANY PROFILES (Page No. – 103)
12.1 ORACLE
12.2 MEDIDATA SOLUTIONS
12.3 PAREXEL (ACQUIRED BY PAMPLONA CAPITAL MANAGEMENT)
12.4 BIOCLINICA
12.5 BIO-OPTRONICS
12.6 IBM
12.7 DATATRAK
12.8 VEEVA SYSTEMS
12.9 DSG
12.10 MASTERCONTROL
12.11 ERT
12.12 FORTE RESEARCH SYSTEMS
12.13 MEDNET SOLUTIONS
12.14 ARISGLOBAL
12.15 ANJU SOFTWARE
12.16 AXISIT
12.17 TECHSOL CORPORATION
12.18 OPENCLINICA
12.19 CRF HEALTH
12.20 COVANCE INC.



★調査レポート[リスクベース監視ソフトウェアの世界市場予測:エンドユーザー別(製薬&バイオ製薬株式会社、医療機器株式会社、CRO)、配信モード別(Webホスト、オンプレミス、クラウドベース)、タイプ別(エンタープライズ、サイト)、コンポーネント別(ソフトウェア、サービス)] ( Risk-based Monitoring Software Market by End User (Pharma & Biopharmaceutical Co., Medical Device Co., CROs), Delivery Mode (Web Hosted, On-premise, Cloud-based), Type (Enterprise, Site), Component (Software, Services) - Global Forecast to 2025 / HIT 7651) 販売に関する免責事項
[リスクベース監視ソフトウェアの世界市場予測:エンドユーザー別(製薬&バイオ製薬株式会社、医療機器株式会社、CRO)、配信モード別(Webホスト、オンプレミス、クラウドベース)、タイプ別(エンタープライズ、サイト)、コンポーネント別(ソフトウェア、サービス)] ( Risk-based Monitoring Software Market by End User (Pharma & Biopharmaceutical Co., Medical Device Co., CROs), Delivery Mode (Web Hosted, On-premise, Cloud-based), Type (Enterprise, Site), Component (Software, Services) - Global Forecast to 2025 / HIT 7651) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆